Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: TES

Gene summary for TES

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

TES

Gene ID

26136

Gene nametestin LIM domain protein
Gene AliasTESS
Cytomap7q31.2
Gene Typeprotein-coding
GO ID

GO:0008150

UniProtAcc

A4D0U5


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
26136TESLZE4THumanEsophagusESCC1.74e-075.40e-010.0811
26136TESLZE8THumanEsophagusESCC1.34e-062.98e-010.067
26136TESLZE22THumanEsophagusESCC9.64e-069.97e-010.068
26136TESLZE24THumanEsophagusESCC1.89e-221.06e+000.0596
26136TESLZE6THumanEsophagusESCC2.29e-061.48e-010.0845
26136TESP1T-EHumanEsophagusESCC1.84e-068.10e-010.0875
26136TESP2T-EHumanEsophagusESCC3.23e-142.63e-010.1177
26136TESP4T-EHumanEsophagusESCC4.69e-195.91e-010.1323
26136TESP5T-EHumanEsophagusESCC1.54e-256.61e-010.1327
26136TESP8T-EHumanEsophagusESCC2.37e-268.06e-010.0889
26136TESP9T-EHumanEsophagusESCC2.49e-105.23e-010.1131
26136TESP10T-EHumanEsophagusESCC7.98e-288.05e-010.116
26136TESP11T-EHumanEsophagusESCC9.01e-099.51e-010.1426
26136TESP12T-EHumanEsophagusESCC5.05e-237.09e-010.1122
26136TESP15T-EHumanEsophagusESCC2.33e-401.40e+000.1149
26136TESP16T-EHumanEsophagusESCC1.99e-175.03e-010.1153
26136TESP17T-EHumanEsophagusESCC1.03e-044.83e-010.1278
26136TESP20T-EHumanEsophagusESCC5.15e-431.50e+000.1124
26136TESP21T-EHumanEsophagusESCC1.72e-371.09e+000.1617
26136TESP22T-EHumanEsophagusESCC8.12e-031.34e-010.1236
Page: 1 2 3 4 5 6 7 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0072659ColorectumADprotein localization to plasma membrane122/3918284/187232.86e-171.49e-14122
GO:1990778ColorectumADprotein localization to cell periphery129/3918333/187235.51e-141.15e-11129
GO:0031647ColorectumADregulation of protein stability108/3918298/187236.33e-105.08e-08108
GO:1902600ColorectumADproton transmembrane transport66/3918157/187231.59e-091.17e-0766
GO:0034329ColorectumADcell junction assembly136/3918420/187232.02e-081.15e-06136
GO:0050821ColorectumADprotein stabilization73/3918191/187233.02e-081.64e-0673
GO:0150115ColorectumADcell-substrate junction organization44/3918101/187232.38e-079.81e-0644
GO:0031589ColorectumADcell-substrate adhesion116/3918363/187234.68e-071.76e-05116
GO:0007044ColorectumADcell-substrate junction assembly41/391895/187238.20e-072.85e-0541
GO:0030099ColorectumADmyeloid cell differentiation119/3918381/187231.24e-064.01e-05119
GO:0002028ColorectumADregulation of sodium ion transport36/391890/187232.89e-055.37e-0436
GO:0007160ColorectumADcell-matrix adhesion75/3918233/187233.56e-056.45e-0475
GO:0048041ColorectumADfocal adhesion assembly34/391887/187238.30e-051.30e-0334
GO:0010765ColorectumADpositive regulation of sodium ion transport17/391835/187232.48e-043.13e-0317
GO:1902305ColorectumADregulation of sodium ion transmembrane transport27/391868/187233.19e-043.80e-0327
GO:0051604ColorectumADprotein maturation85/3918294/187236.73e-046.91e-0385
GO:2000649ColorectumADregulation of sodium ion transmembrane transporter activity23/391858/187238.82e-048.53e-0323
GO:0061458ColorectumADreproductive system development116/3918427/187231.11e-031.01e-02116
GO:1902307ColorectumADpositive regulation of sodium ion transmembrane transport11/391821/187231.43e-031.22e-0211
GO:0048608ColorectumADreproductive structure development114/3918424/187231.78e-031.47e-02114
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
TESSNVMissense_Mutationc.334N>Ap.Glu112Lysp.E112KQ9UGI8protein_codingdeleterious(0.01)probably_damaging(0.93)TCGA-AR-A24H-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapytamoxiphenSD
TESSNVMissense_Mutationc.682N>Ap.Glu228Lysp.E228KQ9UGI8protein_codingtolerated(0.79)benign(0.022)TCGA-BH-A0H5-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycytoxanCR
TESSNVMissense_Mutationnovelc.437G>Ap.Arg146Glnp.R146QQ9UGI8protein_codingdeleterious(0.02)probably_damaging(0.996)TCGA-GM-A5PX-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexCR
TESSNVMissense_Mutationc.916N>Ap.Glu306Lysp.E306KQ9UGI8protein_codingdeleterious(0)probably_damaging(0.991)TCGA-IR-A3LK-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycisplatinPD
TESinsertionFrame_Shift_Insnovelc.698_699insTGGCp.Gln233HisfsTer16p.Q233Hfs*16Q9UGI8protein_codingTCGA-DS-A1OA-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycarboplatinPD
TESSNVMissense_Mutationrs199726977c.97N>Ap.Glu33Lysp.E33KQ9UGI8protein_codingdeleterious(0.01)possibly_damaging(0.79)TCGA-A6-6141-01Colorectumcolon adenocarcinomaMale<65I/IIChemotherapy5-fuSD
TESSNVMissense_Mutationc.863A>Gp.Tyr288Cysp.Y288CQ9UGI8protein_codingdeleterious(0.02)benign(0.075)TCGA-A6-6653-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
TESSNVMissense_Mutationc.829N>Ap.Asp277Asnp.D277NQ9UGI8protein_codingdeleterious(0.03)possibly_damaging(0.856)TCGA-AA-3864-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
TESSNVMissense_Mutationrs199726977c.97G>Ap.Glu33Lysp.E33KQ9UGI8protein_codingdeleterious(0.01)possibly_damaging(0.79)TCGA-AA-3984-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
TESSNVMissense_Mutationc.692G>Tp.Arg231Ilep.R231IQ9UGI8protein_codingtolerated(0.1)benign(0.01)TCGA-AA-3984-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1